Overcoming immune suppression and rebalancing the immune response in ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This translational project collects bone marrow, blood, peritoneal fluid, spleen, and tumor biopsies from women with newly diagnosed ovarian cancer undergoing primary or interval debulking, alongside control samples from women having benign gynecologic surgery. Researchers will profile myeloid progenitor cells and other immune cell populations to map tumor-induced changes in the bone marrow and tumor microenvironment. Ex vivo experiments will test whether nanoparticles or other agents can modify these cells to reduce immune suppression. The goal is to identify immune mechanisms and potential targets that could inform new immunotherapy strategies for ovarian cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects should be at least 18 years old and mentally competent;
* Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking;
* Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia.

Exclusion Criteria:

* Mentally incompetent;
* Pregnant or breastfeeding;
* Known inflammatory of infectious diseases or an immunosuppressive status;
* Using medication interfering with the immune system;
* Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas);
* Serious psychiatric pathology;
* A self reported alcohol consumption of \>21 units per week.

Where it's running

• Catharina Hospital
  Eindhoven, North Brabant, Netherlands Recruiting

Study contacts

• Study coordinator: Jurgen Piek, MD, PhD
• Email: jurgen.piek@catharinaziekenhuis.nl
• Phone: 00310402399300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Testing a new communication tool for ovarian cancer patients and their caregivers

  This study is testing a new communication tool to see if it helps ovarian cancer patients, their caregivers, and doctors work better together in planning care.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06543537

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions

  This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07280312

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.